Blood supply in Melaoma Xenografts is governed by the morphology of the supplying articles 1

Neoplasia

Volumn 11, Issue 3, 2009, Pages 277-285

  Gaustad, Jon Vidar ^a   Simonsen, Trude G ^a   Brurberg, Kjetil G ^a   House, Else Marie ^a   Rofstad, Einar K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL DIAMETER; FEMALE; HUMAN; HUMAN CELL; IMAGING; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TIME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; ARTERY; EXPERIMENTAL MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; VASCULARIZATION; XENOGRAFT;

ANIMALS; ARTERIES; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 62549121683     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81400     Document Type: Article

References (32)

1. Vaupel P (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radial Oncol 14, 198-206.
2. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
3. Brown JM and Giaccia AJ (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
4. Rofstad EK (2000). Microenvironment-induced cancer metastasis. Int J Radiat Bio l76, 589-605.
5. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, and Vaupel P (1989). Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49, 3759-3764.
6. Jain RK (1988). Determinants of tumor blood flow: a review. Cancer Res 48, 2641-2658.
7. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, and Jain RK (1996). Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 51, 327-346.
8. Dewhirst MW, Ong ET, Braun RD, Smith B, Klitzman B, Evans SM, and Wilson D (1999). Quantification of longitudinal tissue PO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 79 1717-1722.
9. Baish JW and Jain RK (2000). Fractals and cancer. Cancer Res 60, 3683-3688.
10. Staufner D and Aharony A (1992). Introduction to Percolation Theory. London, UK: Taylor & Francis.
11. Less JR, Skalak TC, Sevick EM, and Jain RK (1991). Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51, 265-273.
12. Sevick EM and Jain RK (1989). Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49, 3506-3512.
13. Less JR, Posner MC, Skalak TC, Wolmark N, and Jain RK (1997). Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4, 25-33.
14. Øye KS, Gulati G, Graff BA, Gaustad JV, Brurberg KG, and Rofstad EK (2008). A novel method for mapping the heterogeneity in blood supply to normal and malignant tissues in the mouse dorsal window chamber. Microvasc Res 75, 179-187.
15. Rofstad EK (1994). Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. Br J Cancer 70, 804-812.
16. Rofstad EK, Wahl A, Davies CL, and Brustad T (1986). Growth characteristics of human melanoma multicellular spheroids in liquid-overlay culture: comparisons with the parent tumour xenografts. Cell Tissue Kinet 19, 205-216.
17. Brurberg KG, Gaustad JV, Mollatt CS, and Rofstad EK (2008). Temporal heterogeneity in blood supply in human tumor xenografts. Neoplasia 10, 727-735.
18. Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, and Rofstad EK (2008). Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. Neoplasia 10, 354-362.
19. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
20. Gillies RJ, Schornack PA, Secomb TW, and Raghunand N (1999). Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1, 197-207.
21. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
22. Rofstad EK and Halsør EF (2000). Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60, 4932-4938.
23. Rofstad EK and Graff BA (2001). Thrombospondin-l-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J Invest Dermatol 117, 1042-1049.
24. Degner FL and Sutherland RM (1998). Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic, and experimental implications. Int J Radiat Oncol Biol Phys 15, 391-397.
25. Hirst DG and Wood PJ (1991). Could manipulation of the binding affinity of haemoglobin for oxygen be used clinically to sensitize tumours to radiation? Radiother Oncol 20 (Suppl 1), 53-57.
26. Dewhirst MW (1998). Concepts of oxygen transport at the mictocirculatory level. Semin Radiat Oncol 8, 143-150.
27. Fenton BM, Rofstad EK, Degner FL, and Sutherland RM (1988). Cryospectrophotometric determination of tumot intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth. J Natl Cancer Inst 80, 1612-1619.
28. 31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Cancer Res 48, 5440-5446.
29. Horsman MR (1995). Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol 34,571-587.
30. Chaplin DJ, Hill SA, Bell KM, and Tozer GM (1998). Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol 8, 151-163.
31. Vaupel P, Mayer A, and Höckel M (2006). Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 182, 63-71.
32. Batchelor TT, Sørensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP Chen PJ, Zhu M, et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.